Pharma Focus Asia

Bristol Myers Squibb Invests US$400 million to Expand Sterile Drug Product Facility in Dublin, Ireland

Introduction:

Bristol Myers Squibb invests US$400 million to expand its campus in Dublin, Ireland, by incorporating a new sterile drug product facility.

Features:

The investment aims to expand manufacturing and laboratory capacity in Cruiserath, with a focus on supporting the manufacturing of bulk drug substance (SDP). This expansion will involve the integration of new technologies and capabilities into the existing operations.

The campus will incorporate advanced technologies and capabilities to further support the manufacturing of SDP. By colocating drug substance and drug product manufacturing alongside existing global testing capabilities, this strategic move enhances agility in the global supply chain, benefiting patients worldwide.

The expansion is expected to generate approximately 350 new roles in Ireland. These positions will contribute to workforce, with the total number of direct employees at the Cruiserath campus projected to exceed 1,000.

In efforts to strengthen the commercial and pipeline portfolio across multiple therapeutic domains including oncology, immunology, and haematology, an additional 350 roles are anticipated to be created in Ireland as part of this investment.

Construction is set to commence in March 2024, following planning approval, with completion expected in 2026.

Specifications:

Name      Bristol Myers Squibb
Type        Expansion
Budget    US$400 million
Year         2026
 

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference